Skip to content

Effect of polypody rhizome on premenstrual symptoms

Effect of Bisfayej in Premenstrual Syndrome: A Randomised Controlled Study - -

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/01/017118
Enrollment
66
Registered
2019-01-17
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R398- Other symptoms and signs involvingthe genitourinary system

Interventions

Intervention1: Bisfayej (Polypodium vulgare Linn): Fine powder of Bisfayej (Polypodium vulgare Linn),2gm will be given orally in capsules, twice daily from day 16 of the menstrual cycle to day 5 of th

Sponsors

National Institute of Unani Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients having a regular spontaneous menstrual cycle of 21 to 35 days presenting with signs and symptoms of premenstrual syndrome. Patients having symptoms of PMS for atleast 3 menstrual cycles as per ACOG guidelines.

Exclusion criteria

Exclusion criteria: Patients presenting with irregular menstrual cycle. Patients on oral contraceptives and lactating women. Patients having any unstable medical illness and seizure disorder. Diagnosed cases of psychosocial stresses, family, mood andpersonality stresses or depression disorders. Patients with any systemic and endocrineillness like diabetes mellitus, thyroid dysfunction.

Design outcomes

Primary

MeasureTime frame
Change in Premenstrual syndrome symptomsTimepoint: At baseline, after 1st, 2nd, 3rd and 4th menstrual cycle

Secondary

MeasureTime frame
Change in quality of life assessed by EQ-5D-5L questionnaireTimepoint: At baseline, After third menstrual cycle and fourth menstrual cycle

Countries

India

Contacts

Public ContactMarhaba Khanam

National Institute of Unani Medicine

drarshiya@yahoo.com9740915911

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026